What's new
READ-OUT celebrates a milestone as its 15th clinical site accepts participants for the Blood Biomarker Challenge study
4 August 2025
DPUK's READ-OUT study, part of the Blood Biomarker Challenge, has reached a major milestone with the commissioning of its 15th clinical site to the study. It now has half of its planned 30 sites operational, recruiting participants to the study.
Promising news about a 'next gen' drug and nexus of the a global research network - AAIC25 take-aways
1 August 2025
It may have been 5 long days in Toronto for our DPUK delegation, but AAIC25 has been full of announcements, opportunities and insights. Whether you are in the early stages of your career or a relative veteran in dementia research, there has been plenty to take away and consider. I asked three of our DPUK team about what they are taking away from the conference.
Cost too high, benefit too small. No new drugs on the NHS
23 June 2025
The NHS will not be offering patients two new drugs that slow progression of Alzheimer’s Disease following a decision by the regulator, NICE. They have assessed that donanemab and lecanemab provide only a small benefit which does not justify the high cost to the health service.
Latest AI and synthetic data workshop in Birmingham
6 June 2025
DPUK’s Data Portal team is hosting the latest of a series of workshops about AI in research in collaboration with the UK Synthetic Data Community Group in Birmingham on 20th June. Registration is FREE and there is help available for the cost of travel.
How is Dementias Platform UK enhancing research into dementia?
Watch this introductory video about Dementias Platform UK (DPUK) and how it is bringing together the best scientific minds and global leaders in the pharmaceutical industry to find new ways of detecting, treating and preventing dementia.
Get the DPUK newsletter
Sign up to subscribe to the DPUK newsletter.
Keep up to date with all that's going on at Dementias Platform UK. There are around 4 newsletters a year, which include news about developments in our infrastructure services, studies, partnerships and collaborations.
Social Media
We're currently active on LinkedIn, X (Twitter) and BlueSky where we post about every aspect of DPUK. Most of our news is shared on these channels first including jobs, new studies, programme's milestones, information on training, seminars and conferences.
Science feature
UK Biobank completes its 100,000th whole body scan. How its helping dementia research
UK Biobank passes a huge milestone in its whole body imaging programme (and how DPUK contributed).
The DPUK Data Portal gives researchers rapid, secure access to multimodal datasets and millions of health research records.
Our Trials Delivery Framework matches public volunteers to the right dementia studies and has over 80 clinical sites across the UK.
DPUK's Experimental Medicine Incubator accelerates and de-risks the development of new treatments for dementia.
Work with us
Would you like to increase the international visibility of your data? Try our Data Portal.
Do you need well-characterised volunteers for your early-phase trial? Use our Trials Delivery Framework.
Is there a mechanism you would like to investigate? Explore our Experimental Medicine Incubator.